Clozapine Augmented with Glutamate Modulators in Refractory Schizophrenia: A Review and Metaanalysis
oping new medications for schizophrenia. Glutamatergic modulators specifi cally target psychopathological dysfunctions in schizophrenia by reversing the NMDA receptor defi ciency or reducing excessive presynaptic glutamate release [ 8 ] . Although the exact mechanism of clozapine is still unknown, clozapine is hypothesized to infl uence glutamatergic neurotransmission in diff erent ways [ 9 , 10 ] . To determine the effi cacy of several clozapine augmentation strategies with glutamatergic modulators in refractory schizophrenia, fi rst we reviewed glutamate agonists as adjunctive therapy to clozapine. The results of 3 trials on glycine are combined to assess effi cacy for positive, negative and overall symptom severity. We then reviewed glutamate antagonists as add-on therapy to clozapine and conducted metaanalyses of the eff ects of lamotrigine and topiramate on positive, negative and overall symptoms of schizophrenia.
Methods

▼
A search was carried out in the electronic databases PsycINFO, EMBASE, EBM reviews-Cochrane Database of Systematic Reviews, and EBM reviews-Cochrane Central Register of Controlled Trials. Key words were "schizophrenia", "clozapine", "augmentation or combination", "treatment resistant or refractory", "randomized". Titles,
Introduction
▼
Clozapine has proven effi cacy and is the only antipsychotic drug licensed for treatment-resistant schizophrenia [ 1 ] . Patients with an incomplete response to treatment are referred to as 'treatment-resistant' or 'treatment-refractory'. Findings of several cost-eff ectiveness studies consistently favour clozapine over fi rst-generation antipsychotics on measures of clinical efficacy, cost and cost-eff ectiveness, refl ected in gains in life expectancy and quality-adjusted life expectancy [ 2 ] . In spite of its superior effi cacy, 4 % of all patients with schizophrenia do not respond to clozapine at all and approximately one third to one half of the patients treated with clozapine still present with signifi cant residual psychotic symptoms and negative symptoms [ 2 -4 ] . The number of poor-outcome patients who respond partially or not at all to clozapine is substantial and the cost of their medical care is high. There is no convincing evidence regarding the effi cacy of clozapine add-on therapy with nonglutamatergic medication, such as a second antipsychotic, ethyl eicosapentaenoic acid (E-EPA), an antidepressant or a mood stabilizer [ 5 , 6 ] . However, the glutamate hypothesis of schizophrenia suggests that drugs modulating disrupted glutamate pathways may reduce the symptoms of schizophrenia [ 7 ] . Functional psychopharmacotherapy off ers a solution for devel-abstracts and related articles were examined and randomized double-blind studies of patients with clozapine-resistant schizophrenia and clozapine augmentation with glutamatergic medication were selected. There were no language or year of publication restrictions. Open-label studies were not included in the current review. In some studies on glutamate modulators patients received other second-generation antipsychotics than clozapine and fi rst-generation antipsychotics. Those studies were excluded from this review if we were unable to retrieve data on the effi cacy of clozapine augmentation. We will discuss the effi cacy of glutamate modulators in combination with antipsychotics in general in a review on the glutamate hypothesis [ 11 ] and present the results of post-hoc analyses on patients receiving clozapine in 3 lamotrigine trials by Kremer et al., 2004 , studies 464 and 926 by Goff et al., 2007 [ 12 , 13 ] and one topiramate trial by Tiihonen et al., 2005 [ 14 ] . 2 independent reviewers extracted data from the articles and assessed effi cacy. Disagreements were resolved by consensus. Calculations were executed using Comprehensive Meta-Analysis Version 2.0 by Biostat [ 15 ] . Eff ect sizes (ES) and P-values were calculated for the mean diff erence between change scores (endpoint minus baseline scores) of the augmentation group vs. control using Hedges's g [ 16 ] . In order to avoid overestimation of the true eff ect size, change scores were preferred over pre-and posttreatment scores. Pre-and post-treatment means or exact F, t or p-values for main eff ect of treatment group (augmentation or placebo) were used when change scores were not reported. [ 17 , 12 , 18 , 14 ] . A post-hoc analysis was performed with the original data on patients receiving clozapine in study 926 by Goff et al. (2007) [ 13 ] . We conducted 3 metaanalyses on the total Positive and Negative Syndrome Scale (PANSS) score, the positive and negative subscores of the PANSS. We used Brief Psychiatric Rating Scale (BPRS) scores if PANSS scores were not available. We preferred Scale for the Assessment of Negative Symptoms (SANS) above PANSS negative subscale or BPRS-negative subscale to assess negative symptoms. In all 3 analyses Hedges's g was used as a formulation for the standard mean diff erence (SMD). Because of the heterogeneity in the methods applied and the limited number of studies, a random eff ects model was chosen, allowing for greater generalization [ 19 , 20 ] . We calculated homogeneity statistic I 2 to determine whether studies could be taken together to share a common population eff ect size [ 21 ] . High heterogeneity (i. e., I 2 ≥ 50 %; 30-50 % was considered moderate) indicates heterogeneity of the individual study eff ect sizes, posing a limitation to a reliable interpretation of the results. Potential outlier studies were excluded from the metaanalysis. The fi rst metaanalysis was applied in order to pool the fi ndings of 3 glycine studies. The other 2 metaanalyses were performed to assess the eff ect of lamotrigine and topiramate as add-on therapy to clozapine on overall, positive and negative symptoms of schizophrenia.
Results
▼
Glutamate agonists
Glutamate agonists in combination with clozapine have no eff ect on symptoms of schizophrenia, cognitive functioning or aff ective symptoms ( • ▶ Table 1A , B ) [ 22 -28 ] , with the apparent exception of ampakine CX516, a positive modulator of the AMPA receptor: with this agent, negative, overall clinical symptoms and cognitive functioning all improved signifi cantly after 4 weeks [ 27 ] . However, these fi ndings must be regarded as preliminary because of the small sample size and the fact that the ampakine CX516 groups were substantially and signifi cantly more impaired on cognitive function than the placebo group. Ampakine CX516 was well tolerated. The short trial duration in 6 of 7 randomized placebo-controlled trials of clozapine augmentation with glutamate agonists is a limitation in this analysis.
Metaanalysis of glycine
We analyzed the effi cacy of glycine for positive, negative and overall symptoms of schizophrenia in all 3 studies, including a total of 57 patients [ 22 -24 ] . Glycine treatment was associated 
Glutamate antagonists
We found 12 randomized controlled trials of glutamate antagonists in combination with clozapine in refractory schizophrenia
Lamotrigine
Lamotrigine is an antagonist of postsynaptic voltage-sensitive sodium channels, decreasing presynaptic release of glutamate [ 17 ] .
Of 6 trials on lamotrigine addition to clozapine ( • ▶ Table 2A , B ) [ 17 , 12 , 18 , 13 , 29 ] , 2 studies show promising clinical improvement in outpatients [ 18 , 13 ] . In all 6 studies lamotrigine was well tolerated and no signifi cant diff erences in adverse events were observed in the lamotrigine group vs. placebo group. In a 14-week cross-over trial by Tiihonen et al. (2003) in hospitalized patients with clozapine-resistant schizophrenia, lamotrigine with a maximum dosage of 200 mg/day did not signifi cantly improve positive or negative symptoms [ 17 ] . 21 % of patients in the lamotrigine group showed a reduction of at least 3 points in the PANSS positive symptoms scale vs. 3 % in the placebo group. Subanalyses suggest that those patients with a shorter duration of illness and those patients who are most resistant to clozapine treatment (having high PANSS positive symptom scores) benefi t most from this augmentation strategy [ 30 ] . In a randomized controlled trial by Kremer et al. (2004) 25 hospitalized patients with treatment-resistant schizophrenia were allocated to lamotrigine in addition to their ongoing treatment with antipsychotics, while 13 patients received placebo [ 12 ] . Tiihonen et al. (2009) extracted the data of 4 patients who were on clozapine (1 of these 4 patients completed the trial) [ 31 ] . Lamotrigine was gradually titrated up to 400 mg/day during the last 2 weeks of the 10-week trial. No signifi cant benefi ts could be determined in these few patients. In a study by Zoccali et al. (2007) , placebo or lamotrigine with a maximum dosage of 200 mg/day was gradually added to ongoing clozapine treatment during 8 weeks in outpatients with clozapine-resistant schizophrenia [ 18 ] . Lamotrigine proved to have benefi cial eff ects on positive, negative and overall symptoms of schizophrenia. Cognitive functions did not signifi cantly improve in the lamotrigine group compared with the placebo group, except for semantic fl uency at week 24 (ES = 1.01). Goff et al. (2007) conducted 2 trials (study 464 and study 926) in predominantly outpatients with residual psychotic symptoms [ 13 ] . Lamotrigine was gradually titrated up to 200 mg/day in the fi rst 6 weeks, and in some cases increased up to a maximum of 400 mg/day (mean lamotrigine doses achieved were 205 mg/day in study 464 and 241 mg/day in study 926). Trial duration was 12 weeks. Unlike study 464, which did not fi nd signifi cant diff erences in positive, negative and overall symptoms of schizophrenia compared with the placebo group, study 926 found a signifi cant positive eff ect on negative symptoms. Table 1 Fig . 1 a Metaanalysis of glycine augmentation of clozapine for positive symptom score (PANSS-P/ BPRS-P). Table 1   Table 3 Double-blind, placebo-controlled randomized trials of clozapine augmentation with topiramate in refractory schizophrenia. Table 1   Table 4 Double-blind, placebo-controlled randomized trials of clozapine augmentation with memantine in refractory schizophrenia. Table 1 200 mg/day and 400 mg/day showed benefi cial eff ects in 2 separate studies. Therefore, no conclusions regarding optimal dosage can be given. Diff erent titration schemes in the above- 
Study
Metaanalysis of lamotrigine
Results on positive, negative and overall symptom severity were combined in a metaanalysis of all 6 studies, including a total of 185 patients [ 17 , 12 , 18 , 13 , 29 ] . Lamotrigine in addition to clozapine did not signifi cantly change positive symptoms compared to placebo, but a trend towards reducing positive symptoms was found (ES = 0.314, p = 0.065; 95 %CI = − 0.020 to 0.648) ( • ▶ Fig. 2a ). 
Studies were homogeneous (
Topiramate
Topiramate has a mixed profi le of both gamma-aminobutyric acid (GABA)-ergic and antiglutamatergic actions [ 14 , 33 ] . Presynaptic glutamate release is reduced because topiramate is an antagonist for postsynaptic kainate receptors and amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors. 2 out of 4 trials with topiramate added to clozapine show beneficial eff ects in refractory schizophrenia ( • ▶ Table 3 ) [ 34 , 35 ] . In 3 trials topiramate augmentation was found to be well tolerated and adverse events did not diff er signifi cantly between the topiramate group and the placebo group [ 14 , 34 , 35 ] , but in another study 30 % of topiramate subjects failed to complete the trial due to side eff ects such as sleepiness, ataxia, psychomotor slowness and exacerbation of positive symptoms [ 33 ] . This difference may be due to the short titration scheme in this trial, with a 50 mg/day increment every 2 days (in 6 days increase of topiramate to 200 mg or in 10 days increase of topiramate to 300 mg). One out of 3 studies found clinical improvement in hospitalized patients with treatment-resistant schizophrenia after topiramate augmentation [ 14 , 34 , 33 ] . In a study by Afshar et al. (2008) topiramate proved to be effi cacious, with a signifi cant decrease in negative and positive symptoms and an impressive clinical response (defi ned as > 20 % reduction in PANSS) in 50 % of topiramate-treated subjects vs. 12.5 % in controls [ 34 ] . In the Tiihonen et al. study (2005) 22 patients received topiramate in addition to their ongoing atypical antipsychotic medication and 23 patients received placebo over two 12-week cross-over treatment periods [ 14 ] . A subanalysis of 14 patients receiving clozapine did not show signifi cant improvement in positive, negative and overall symptoms of schizophrenia compared to placebo. The study by Behdani et al. (2011) even found more improvement in positive and negative symptoms of schizophrenia in the placebo group than in the topiramate group; however, this diff erence was not signifi cant [ 33 ] . The effi cacy of topiramate augmentation of clozapine was confi rmed in a single study of outpatients by Muscatello et al. (2010) [ 35 ] . Positive and negative symptoms improved signifi cantly after a relatively long treatment duration of 24 weeks with a topiramate dosage of only 200 g/day compared to placebo.
Meta-analysis of topiramate
The combined results of all 4 studies ( N = 152) showed topiramate to have similar eff ects to placebo for positive symptoms . 3a ) [ 14 , 34 -33 ] . Studies showed large heterogeneity ( I 2 = 64.549 %).
Topiramate was not superior to placebo treatment for negative symptoms either (ES = 0.400, p = 0.321; 95 %CI = − 0.390 to 1.189) ( • ▶ Fig. 3b ). Studies were highly heterogeneous ( I 2 = 81.395 %).
For overall symptom severity we analyzed 3 studies ( N = 89) [ 14 , 34 , 35 ] . Topiramate studies yielded no signifi cant diff erence between topiramate and placebo for total symptom score (ES = 0.754, p = 0.068; 95 %CI = − 0.055 to 1.564) ( • ▶ Fig. 3c ). Studies showed high heterogeneity ( I 2 = 69.439 %).
Memantine
Memantine is a voltage-dependent antagonist of the NMDA receptor, which binds more strongly than Mg 2 + [ 36 ] . 
Discussion
▼
With NMDA receptor hypofunction as underlying pathological mechanism of schizophrenia in mind, addition of a glutamate agonist seems a reasonable treatment approach. Addition of NMDA receptor modulators to antipsychotics has additional therapeutic benefi ts due to agonistic activity at the NMDA receptor [ 37 ] . Clozapine is itself a glutamate agonist, which is probably why it has superior antipsychotic effi cacy to dopamine antagonists in treatment-refractory schizophrenia. Clozapine improves glutamatergic neurotransmission in several diff erent ways. Clozapine has preferential antagonist activity at dopamine 4 receptors, resulting in upregulation of AMPA receptors and consequently improvement of glutamatergic neurotransmission [ 9 ] . Clozapine enhances activation of the NMDA receptor through induction of release of D-serine by glial cells. Clozapine also stimulates glial cells to release glutamate, resulting in activation of postsynaptic metabotropic glutamate (mGlu) receptors and upregulation of NMDA receptors [ 10 ] . This leads to improvement in glutamatergic tonus in brain areas such as the prefrontal, thalamic and cerebro-cerebellar regions, which may explain the unique therapeutic eff ect of clozapine. However, when clozapine is combined with a NMDA receptor agonist, selective and concurrent activation of mGlu receptors and NMDA receptors leads to downregulation of NMDA receptors [ 38 ] . This explains why we found no favourable eff ects of NMDA receptor agonists in combination with clozapine in 6 double-blind placebo-controlled randomized trials. The combined results of 3 glycine studies even show signifi cant worsening of positive symptoms compared to placebo. We found one single positive study with a glutamate agonist -ampakine CX516 [ 27 ] . This can be explained by the diff erential eff ect of ampakine CX516: unlike NMDA receptor agonists, ampakine CX516 is a positive modulator of the AMPA receptor and does not activate the NMDA receptor directly. This is why the combination of clozapine and ampakine CX516 does not lead to downregulation of NMDA receptors. We found a signifi cant therapeutic eff ect of lamotrigine augmentation of clozapine in 2 out of 6 trials. Perhaps a lamotrigine dose of 200 mg/day is adequate, since this dosage was effi cacious in reducing positive, negative and overall symptoms of schizophrenia after an eff ective treatment duration of 8 weeks [ 18 ] . However, no conclusions are justifi ed on the basis of this small study. 2 shorter trials with a treatment duration of 4 and 7 weeks, respectively, with the same maximum lamotrigine dose of 200 mg/day, failed to replicate these positive results [ 17 , 29 ] . The combined results of 6 studies showed a trend towards reduction in positive symptoms and negative symptoms. There is scarce and confl icting evidence of the effi cacy of topiramate addition in clozapine-resistant patients. A minimum topiramate dosage of 200 mg/day seems necessary. In 1 out of 2 trials showing a benefi cial eff ect the topiramate dosage was 200 mg/day [ 35 ] . A metaanalysis of topiramate studies showed no signifi cant change or trend compared to placebo. Both lamotrigine and topiramate antagonize excitotoxic actions of glutamate by reduction of presynaptic glutamate release [ 17 , 14 , 33 ] . Memantine emerges as a superior augmentation strategy, with very large eff ect sizes on positive symptoms, negative symptoms, overall clinical symptoms of schizophrenia and cognitive functioning [ 36 ] . However, one small trial does not allow us to draw a defi nitive conclusion. This possible unique therapeutic eff ect of memantine addition to clozapine may be due to the fact that, as an antagonist for NMDA receptors, memantine prevents simultaneous activation of mGlu receptors and NMDA receptors and blocks induction of downregulation of NMDA receptors [ 38 ] . Therefore, the combination of clozapine and memantine results in upregulation of NMDA receptors. Clozapine combined with memantine may ameliorate positive symptoms through enhancement of the projection of glutamate from the orbitofrontal and prefrontal cortex on the amygdala [ 39 ] . In schizophrenia NMDA hypofunction has a disinhibitory eff ect, causing abnormal cortical signal-to-noise patterns with prefrontal noise and reduction of transmission effi cacy of cortical neurons, resulting in negative symptoms and cognitive defi cits, associated with frontal lobe dysfunction [ 40 ] . Memantine is hypothesized to induce a decrease of prefrontal noise. Only a strong stimulus results in activation of the NMDA receptor, resulting in improved glutamatergic tonus and dopaminergic neurotransmission in the frontal cerebral cortex, explaining decrease of negative symptoms and improvement of prefrontal cortexdependent cognitive functions [ 41 ] . Excessive glutamate spillover due to dysfunction of the NMDA system leads to reduced synaptic connections and neuronal excitotoxicity in the PFC, also causing cognitive impairment. In the presence of glutamate spillover in the synaptic cleft, memantine is considered to be a neuroprotective drug, decreasing neuronal cell death [ 40 ] . By preventing the neurotoxic Ca 2 + infl ux, memantine might even be able to attenuate progressive cognitive impairment [ 6 ] . Glutamate antagonists are promising as an adjunctive therapy to clozapine, because this particular combination modulates glutamatergic neurotransmission at multiple levels, acting at the AMPA (clozapine), NMDA (clozapine, memantine and amantadine) and mGlu receptors (clozapine) or aff ecting presynaptic glutamate release (lamotrigine and topiramate). Lamotrigine and topiramate reduce presynaptic glutamate release and antagonize excitotoxic actions of glutamate. To create an improved glutamatergic balance in the brain, study results indicate that suffi cient duration of combination therapy of a glutamate antagonist and clozapine is necessary to achieve an effi cacious response. Limited evidence suggests that a minimum of 200 mg/ day lamotrigine and a minimum of 200 mg/day topiramate may be necessary to achieve response. A metaanalysis of lamotrigine studies showed only a trend towards reduction of residual positive symptoms and negative symptoms, whereas a metaanalysis on topiramate showed no signifi cant diff erence between topiramate and placebo. Memantine is a voltage dependent low-tomoderate-affi nity channel-blocking NMDA receptor antagonist. Due to these neuroprotective properties memantine is hypothesized to improve cortical signal-to-noise patterns and transmission effi cacy of cortical neurons in schizophrenia. In the presence of glutamate spillover in the synaptic cleft due to NMDA receptor hypofunction, memantine reduces neurotoxic Ca 2 + infl ux. In combination with clozapine memantine blocks concurrent activation of mGlu receptors and NMDA receptors and thus causes upregulation of NMDA receptors. Early intervention with clozapine combined with memantine might interfere with the excitotoxic process, limiting cognitive impairment in schizophrenia. In one small study memantine was found to have an impressive eff ect size after a treatment duration of only 9 weeks with a maximum dosage of 20 mg/day. A subgroup of schizophrenia patients with prevailing negative symptoms might benefi t specifi cally from the combination of clozapine and NMDA receptor antagonists. At present there is no solid evidence indicating how patients with schizophrenia suff ering from clozapine-resistant symptoms can be helped [ 5 , 6 ] . Glutamate antagonists are a promising augmentation strategy. Memantine seems the most promising candidate, because it improves the expression and regulation of NMDA receptors. Signifi cant effi cacy (with large eff ect sizes) for all symptoms of schizophrenia, including cognitive functioning, was demonstrated in one small study. Large-scale, placebo-controlled trials are required to determine the effi cacy, safety and suffi cient duration of adjunctive therapy with glutamate antagonists in clozapine-resistant patients.
